The impacts of tobacco and nicotine on HIV-1 infection, inflammation, and the blood-brain barrier in the central nervous system.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic pathways without systematic review methodology or primary clinical data.
PubMed 39529883 · doi:10.3389/fphar.2024.1477845
What was done
This paper is a narrative review synthesizing literature on how tobacco and nicotine interact with HIV-1 infection in the central nervous system. It examines biological mechanisms related to cognition, neuroinflammation, viral latency, blood-brain barrier integrity, and shared signaling through the NLRP3 inflammasome.
What was found
No quantitative findings, sample sizes, effect sizes, or statistical metrics are reported in the abstract. The authors propose conceptual mechanisms whereby nicotine modulates central nervous system inflammatory pathways through the NLRP3 inflammasome, potentially contributing to active and latent HIV-1 brain infection and worsening HIV-associated neurocognitive disorder.
Why it matters
Understanding how nicotine impacts neuroinflammation provides mechanistic insight into why tobacco-using individuals with HIV remain at higher risk for cognitive impairment despite effective viral suppression.
Limits
As a narrative review, it contains no primary clinical data, quantitative meta-analysis, or systematic search criteria in the abstract. The described mechanisms rely on theoretical and preclinical frameworks without empirical effect estimates in human populations.
Cited by
- supports Blood-brain barrier integrity and effectiveness decline with aging, diabetes, and cigarette smoking.